Vasopressin Neutralizing Antibody

About Corteria Pharmaceuticals

Corteria Pharmaceuticals is a privately held, clinical-stage biotech based in Paris, developing novel small molecule and biologic therapies for cardiovascular and metabolic disorders. The company's lead programs are two first-in-class CRF2 receptor agonists targeting worsening heart failure and obesity/right heart failure, with one asset entering Phase 2 and another in Phase 1. Leveraging deep cardiovascular R&D expertise from its leadership, Corteria aims to address significant unmet needs in heart failure decompensation through a precision medicine approach.

Therapeutic Areas